Oncology Research and Treatment

 

Sequentielle Chemotherapie maligner Non-Hodgkin-Lymphome (NHL) von hohem Malignitätsgrad im Stadium III und IV

Mitrou P.S.a · Fischer M.a · Bergmann L.a · Hübner K.b

Author affiliations

aZentrum der Inneren Medizin, Abteilung für Hämatologie/Onkologie und bSenckenbergisches Zentrum der Pathologischen Anatomie der Universität, Frankfurt/M.

Related Articles for ""

Onkologie 1982;5:222–227

Log in to MyKarger to check if you already have access to this content.


Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: April 21, 2009
Issue release date: 1982

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 0

ISSN: 2296-5270 (Print)
eISSN: 2296-5262 (Online)

For additional information: https://www.karger.com/ORT

Abstract

Maligne Non-Hodgkin-Lymphome (NHL) von hohem Malignitätsgrad der Kieler Klassifikation wurden vom Juli 1978 bis August 1980 mit einer sequentiellen Chemotherapie behandelt. Nach der Kombination von Cyclophosphamid, Vincristin, Bleomycin und Prednison (Phase A) wurde die Kombination von Adriamycin, Cytosin Arabinosid, 6-Thioguanin und Prednison (Phase B) gegeben. Die Patienten erhielten 4 Zyklen beider Kombinationen ohne anschließende Erhaltungstherapie. 20 Patienten mit zentroblastischem, immunoblastischem oder lympho-blastischem NHL wurden in die Studie aufgenommen. Bei 95% (19 der 20 Patienten) der Patienten wurde eine komplette oder partielle Remission induziert. Die Rate kompletter Remissionen betrug 75% (15 der 20 Patienten). Die mediane Dauer der kompletten Remissionen betrug 28,7 Monate. Die statistische Überlebenswahrscheinlichkeit nach 2 Jahren beträgt für die Patienten mit kompletter Remission 64,5%. Klinische prognostische Faktoren (Knochenmarkinfiltration, Befall extralymphatischer Organe, Lymphome mit einem Durchmesser von mehr als 10 cm) beeinflussen entscheidend die Remissionsinduktion und die Überlebenszeit. Alle Patienten mit günstiger Prognose überleben in kompletter Remission 14-38 Monate nach Therapiebeginn. Die Kranken mit ungünstiger Prognose haben eine Remissionsrate von 64% und eine mediane Überlebenszeit von 14,8 Monaten.

© 1982 S. Karger AG, Basel




Related Articles:


Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: April 21, 2009
Issue release date: 1982

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 0

ISSN: 2296-5270 (Print)
eISSN: 2296-5262 (Online)

For additional information: https://www.karger.com/ORT


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
TOP